In Brief: Bio-Vascular
This article was originally published in The Gray Sheet
Executive Summary
Bio-Vascular: Expects accelerated European sales of its Peri-Strips Dry bovine pericardium-based staple line reinforcements in late 1997, when the company is scheduled to complete multi-center trials evaluating use of the products in lung volume reduction procedures performed on patients suffering from late-stage emphysema. The company commenced U.S. sales of the product, which replaces an earlier version of the Peri-Strips device, in mid-July following FDA clearance in early May...
You may also be interested in...
Surgical Sealants, Inc. Hoping To Debut SurgiSeal Vascular Sealant In 2000
Development stage Surgical Sealants, Inc. is currently conducting clinical trials of its collagen-based SurgiSeal vascular sealant and expects to submit a 510(k) to FDA by year-end.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.